SESN2 and breast cancer: Treatment of MCF7 and HCC1806 (triple negative P53−/− breast cancer cell line) cells with a range of chemotherapeutics detected elevated SESTRIN 2 expression following treatment with the anti-folate drug Mtx and the proteosomal inhibitor Btz (Figure 4A-4B).